The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

A Single Center, Double-Blind, Randomized, Double Dummy, Placebo-Controlled, Three-Period Crossover Study to Assess the Effects of a mGluR2/3 Positive Allosteric Modulator [AZD8529] Upon Ketamine-Induced Cortical Stimulation and Impairment of Working-Memory Related Activation of the Prefrontal Cortex

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00985933

Enrollment

Registered

2009-09-29

Start date

2010-02-28

Completion date

2011-04-30

Last updated

2011-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Memory Impairment

Keywords

Healthy normal volunteers

Brief summary

The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).

Interventions

DRUGAZD8529

6 capsules by mouth 1 time 12 to 24 prior to assessments

DRUGPlacebo to match AZD8529

6 capsules by mouth 1 time 12 to 24 hours prior to assessments

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

21 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Right handed * 12th grade education or equivalent * Able to read and write English as primary language

Exclusion criteria

* History of head injury * Substance abuse or dependence * History of claustrophobia

Design outcomes

Primary

Measure	Time frame
fMRI	3
Ketamine Infusion	3

Secondary

Measure	Time frame
Clinician Administered Dissociative States Scale (CADSS)	—
Positive and Negative Syndrome Scale (PANSS)	—
Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, collection of adverse events	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026